Buy Sulpirid-Belupo capsules 200 mg 12 pcs
  • Buy Sulpirid-Belupo capsules 200 mg 12 pcs


1644 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Sulpiride is an atypical neuroleptic from the group of substituted benzamides.
Sulpiride has moderate neuroleptic activity in combination with stimulating and thymoanaleptic (anti-depressive) effects.
Neuroleptic effect is associated with anti-dopaminergic action. In the central nervous system, sulpiride mainly blocks the dopaminergic receptors of the limbic system, but it has little effect on the non-striated system, it has an antipsychotic effect and causes a small number of side effects.
The peripheral action of sulpiride is based on the inhibition of presynaptic receptors. With an increase in the amount of dopamine in the CNS, an improvement in mood is associated with a decrease in the development of symptoms of depression.

The antipsychotic effect of sulpiride is manifested in doses of more than 600 mg / day, in doses up to 600 mg / day, a stimulating and antidepressant effect prevails.
Sulpiride has no significant effect on adrenergic, cholinergic, serotonin, histamine and gamma-aminobutyric acid receptors (GABA-receptors).
In small doses, sulpiride can be used as an adjunct in the treatment of psychosomatic diseases, in particular, it is effective in relieving the negative mental symptoms of gastric ulcer and duodenal ulcer. In irritable bowel syndrome, sulpiride reduces the intensity of abdominal pain and leads to an improvement in the patient's clinical condition.
Low doses of sulpiride (50-300 mg / day) are effective for dizziness, regardless of etiology. Sulpiride stimulates prolactin secretion and has a central antiemetic effect (inhibition of the emetic center).

After oral administration, plasma Cmax is achieved in 1.5–3 h. The bioavailability of sulpiride is 27%. The binding of sulpiride to plasma proteins is less than 40%. The concentration of sulpiride in the CNS is 2-5% of the concentration in plasma. Sulpiride is excreted in breast milk. Sulpiride in the human body is not metabolized and is excreted almost unchanged through the kidneys. T1 / 2 is 6-8 hours. T1 / 2 is significantly increased in patients with moderate and severe renal insufficiency up to 20-26 hours after IV administration. Such patients should reduce the dose of sulpiride and / or increase the interval between taking the drug.


As monotherapy or in combination with other psychotropic drugs.

  • acute and chronic schizophrenia;
  • acute delirious states;
  • depression of various etiologies;
  • neurotic disorders;
  • dizziness of various etiologies (vertebro-basilar insufficiency, vestibular neuritis, Meniere's disease, condition after a traumatic brain injury, otitis media);
  • adjuvant therapy for gastric ulcer and duodenal ulcer and irritable bowel syndrome.


1 capsulecontains:

Active substances: sulpiride 200 mg;

Excipients:lactose monohydrate, corn starch, pregelatinized corn starch, magnesium stearate, titanium dioxide, gelatin.

Sulpiride is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Sulpirid-Belupo Belupo Croatia capsules
Sulpiride Organica Russia ampoules
Sulpiride Organica Russia pills
Prosulpin PRO.MED.CS Praha a.s Czech pills
Eglonyl® Sanofi-aventis France solution
Eglonyl® Sanofi-aventis France capsules
Eglonyl® Sanofi-aventis France pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Capsules are taken 1-3 times a day, washed down with a small amount of liquid, regardless of the meal.
It is not recommended to take the drug in the afternoon (after 16 h) due to the increased level of activity.

Acute and chronic schizophrenia, acute delirious psychosis, depression: the daily dose ranges from 200 to 1000 mg, divided into several doses.

Neurosis and anxiety in adult patients: the daily dose ranges from 50 to 150 mg for 4 weeks at the most.

Severe behavioral disorders in children: the daily dose is from 5 to 10 mg / kg body weight.

Doses for the elderly: The initial dose of sulpiride should be 1 / 4-1 / 2 doses for adults.

Adverse reactions

On the part of the endocrine system: possible development of reversible hyperprolactinemia, the most frequent manifestations of which are galactorrhea, amenorrhea, menstrual disorders, less often gynecomastia, impotence and frigidity. During treatment with sulpiride, excessive sweating and weight gain may occur.

On the part of the digestive system: increased activity of liver enzymes.

CNS: sedation, somnolence, dizziness, tremor, early dyskinesia (spasmodic torticollis, oculogyric crises, lockjaw), passing in the appointment of an anticholinergic protivoparkinsonnogo means rare - extrapyramidal syndrome and related disorders (akinesia, sometimes combined with muscle hypertonicity and partially eliminated in the appointment of anticholinergic antiparkinsonnyh funds, hyperkinesia-hyper tone, motor agitation, akatasia). There have been cases of tardive dyskinesia, characterized by involuntary rhythmic movements, mainly of the tongue and / or face during long courses of treatment, which can be observed during the course of treatment with all antipsychotics: use of antiparkinsonian drugs is ineffective or may cause worsening of symptoms. With the development of hyperthermia, the drug should be canceled, because an increase in body temperature may indicate the development of neuroleptic malignant syndrome (MNS).

Since the cardiovascular system: tachycardia, it is possible to increase or decrease blood pressure, in rare cases it is possible to develop orthostatic hypotension, prolonged QT interval, very rare cases of the development of the syndrome "torsade depointes".

Allergic reactions: skin rash is possible.


Due to the presence of lactose in the formulation, it is contraindicated for congenital galactosemia, glucose / galactose malabsorption syndrome, or lactase deficiency.

It is not recommended that Eglonyl is prescribed for pregnant women, unless the doctor, having assessed the balance between benefits and risks for the pregnant woman and the fetus, decides that the use of the drug is necessary.

It is not recommended to administer sulpiride in combination with ethanol, levodopa, drugs that can cause ventricular arrhythmias like "torsade de pointes" (class 1a antiarrhythmic drugs (quinidine, hydroquinidine, disopyramide) and class III (amiodarone, sotalol, dofetilide, ibutilide)), some neuroleptic (thioridazine, chlorpromazine, levomepromazine, trifluoperazin, cyamemazine, amisulpride, Tiapride, pimozide, haloperidol, droperidol) and other drugs such as bepridil, cisapride, diphemanil, intravenous erythromycin, intravenous erythromycin, intravenous erythromycin, intravenous erythromycin, intravenous th vincamine, halofantrine, pentamidine, sparfloxacin, moxifloxacin, etc.

Precautions should be taken when prescribing Eglonyl to patients with renal and / or hepatic insufficiency, a history of malignant neuroleptic syndrome, epilepsy or convulsive history, severe heart disease, arterial hypertension, patients with parkinsonism, dysmenorrhea, elderly people.

Drug interactions

Weakens the effect of levodopa, increases the severity of a decrease in blood pressure on the background of antihypertensive drugs; incompatible with alcohol and other drugs that depress the central nervous system (mutual enhancement of sedative properties).

Special instructions

Malignant neuroleptic syndrome: with the development of hyperthermia of undiagnosed origin, Eglonyl should be canceled, as this may be one of the signs of the malignant syndrome described with the use of neuroleptics (pallor, hyperthermia, autonomic dysfunction, impaired consciousness, muscle rigidity)

Signs of autonomic dysfunction, such as increased sweating and abnormal blood pressure, may precede the onset of hyperthermia and, therefore, are early warning signs.

Although this neuroleptic effect may be of idiosyncratic origin, it appears that some risk factors may predispose to it, such as dehydration or organic brain damage.

Increase the QT interval: sulpiride extends the QT interval depending on the dose. This action, which is known to increase the risk of developing severe ventricular arrhythmias, such as "torsade de pointes", is more pronounced in the presence of bradycardia, hypokalemia, or congenital or acquired prolonged QT interval (combination with a drug that causes a prolongation of the QT interval).

If the clinical situation allows, it is recommended before the appointment of Eglonyl to ensure that there are no factors that may contribute to the development of this type of arrhythmia:
- bradycardia with the number of strokes less than 55 beats / min,
- hypokalemia,
- congenital prolongation of the QT interval,
- simultaneous treatment with a drug capable of causing marked bradycardia (less than 55 bpm), hypokalemia, slowing of intracardiac conduction or prolongation of the QT interval.

With the exception of cases of urgent intervention, patients who require treatment with neuroleptics are recommended to conduct an ECG in the status assessment process.

Except in exceptional cases, this drug should not be used in patients with Parkinson's disease.

In patients with impaired renal function, reduced doses should be used and control should be strengthened; in severe forms of renal failure, intermittent treatment is recommended.

The control during treatment with Eglonyl should be strengthened:
- in patients with epilepsy, since the convulsive threshold can be lowered;
- in the treatment of elderly patients exhibiting greater sensitivity to postural hypotension, sedation and extrapyramidal effects.

Alcohol consumption or the use of medications containing ethyl alcohol during the course of drug treatment is strictly prohibited.

During treatment with Eglonyl, it is prohibited to drive vehicles and work with mechanisms that require increased attention, as well as alcohol intake.

  • Brand name: Sulpirid-Belupo
  • Active ingredient: Sulpiride
  • Dosage form: Capsules
  • Manufacturer: Belupo
  • Country of Origin: Croatia

Studies and clinical trials of Sulpiride (Click to expand)

  1. Intermittent withdrawal program of neuroleptics with sulpiride in remitted schizophrenic outpatients
  2. Physical Properties of Sulpiride and Its (S)-Enantiomer
  3. Disposition of enantiomers of sulpiride in humans and rats
  4. ChemInform Abstract: Design, Synthesis and Neuroleptic Activity of Dipeptide Analogues of Sulpiride.
  5. Differential up-regulation of D-1 and D-2 dopamine receptor function in mesostriatal areas but not in cortical-limbic brain regions of rats chronically treated with (—)sulpiride and SCH 23390
  6. Sulpiride and placebo in depressed elderly outpatients: A double-blind study
  7. PCILO and CD. Conformational study of sulpiride, a dopamine antagonist
  8. Acute hypertensive episode induced by sulpiride – a case report
  9. Sulpiride in negative schizophrenia: A placebo-controlled double-blind assessment
  10. Acute extrapyramidal reactions following lithium and sulpiride co-administration: Two case reports
  11. Fluvoxamine and sulpiride in comorbid obsessive–compulsive disorder and gilles de la tourette syndrome
  12. Enhancement by sulpiride of the inhibitory effects of cysteamine on gastric carcinogenesis induced by n-methyl-n'-nitro-n-nitrosoguanidine in wistar rats
  13. Effects of sulpiride on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats
  14. Preparation of N(1-ethyl-2-pyrrolidyl-methyl)2-methoxy-4-iodo-125I- 5-ethyl sulfonyl benzamide: A radioligand for the radioimmunoassay of sulpiride-related compounds
  15. Synthesis of D3-sulpiride and its (R) and (S) isomers
  16. Synthese DU N- [(ethyl - 1 pyrrolidinyl -2) methyl] methoxy-2 sulfamoyl -5 benzamide (sulpiride) marque AU 14C
  17. Isolation, identification, and synthesis of the major sulpiride metabolite in primates
  18. Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels
  19. Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations
  20. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans
  21. Sulpiride-induced tardive dystonia
  22. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride
  23. Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination
  24. Simultaneous electrochemiluminescence determination of sulpiride and tiapride by capillary electrophoresis with cyclodextrin additives

8 other products in the same category: